# United Therapeutics

Organization · id `cardio:org-united-therapeutics` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov sponsor names](<https://clinicaltrials.gov/search?spons=United+Therapeutics>), retrieved 18 November 2026. No person wrote or checked this page.

## In plain language

An organization that ClinicalTrials.gov lists as a sponsor or collaborator of 9 trials in this atlas.

## Technical summary

Sponsor class industry. No ROR record matches the name exactly.

## The registry's words

- Sponsor name: United Therapeutics
- Sponsor class: INDUSTRY

## Connected pages

- Sponsors: Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy (`cardio:ct-nct01560624`)
- Sponsors: An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension (`cardio:ct-nct01560637`)
- Sponsors: Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE (`cardio:ct-nct02630316`)
- Sponsors: An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE (`cardio:ct-nct02633293`)
- Sponsors: A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD) (`cardio:ct-nct03496623`)
- Sponsors: A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients (`cardio:ct-nct03626688`)
- Sponsors: A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension (`cardio:ct-nct03683186`)
- Sponsors: Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension (`cardio:ct-nct06911632`)
- Sponsors: An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) (`cardio:ct-nct07923526`)

## Provenance

Content hash: e3c48a95314ebede85b63a5b462d3a1ffaa5a07c813afb7efd91b7bff51c3c94
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
